Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MBRX Moleculin Biotech Inc
- Stocks
- Healthcare
- NASDAQ: MBRX
Price (delayed)
$0.8712
Market cap
$12.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.73
Enterprise value
$4.92M
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
Highlights
The EPS has surged by 64% year-on-year and by 25% since the previous quarter
MBRX's debt is down by 28% year-on-year and by 9% since the previous quarter
MBRX's quick ratio has dropped by 64% year-on-year but it is up by 40% since the previous quarter
MBRX's net income is up by 13% year-on-year but it is down by 7% since the previous quarter
The company's equity has shrunk by 100% YoY and by 99% QoQ
Key stats
What are the main financial stats of MBRX
Market
Valuations
Earnings
Shares outstanding
14.13M
Market cap
$12.31M
Enterprise value
$4.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
290.41
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$25.91M
Net income
-$23.23M
EBIT
-$23.23M
EBITDA
-$23.1M
Free cash flow
-$21.71M
Per share
Balance sheet
Liquidity
EPS
-$4.73
EPS diluted
-$4.73
Free cash flow per share
-$2.32
Book value per share
$0
Revenue per share
$0
TBVPS
$1.06
Total assets
$21.01M
Total liabilities
$20.97M
Debt
$326,000
Equity
$42,000
Working capital
$2.44M
Debt to equity
7.76
Current ratio
1.35
Quick ratio
1.12
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-106.9%
Return on equity
-297.8%
Return on invested capital
N/A
Return on capital employed
-164.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MBRX stock price
How has the Moleculin Biotech stock price performed over time
Intraday
-8.39%
1 week
-11.09%
1 month
-17.81%
1 year
-82.33%
YTD
-48.75%
QTD
-10.52%
Financial performance
How have Moleculin Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.91M
Net income
-$23.23M
Gross margin
N/A
Net margin
N/A
MBRX's net income is up by 13% year-on-year but it is down by 7% since the previous quarter
MBRX's operating income is up by 7% YoY and by 2.8% from the previous quarter
Price vs fundamentals
How does MBRX's price correlate with its fundamentals
Growth
What is Moleculin Biotech's growth rate over time
Valuation
What is Moleculin Biotech stock price valuation
P/E
N/A
P/B
290.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 64% year-on-year and by 25% since the previous quarter
The company's equity has shrunk by 100% YoY and by 99% QoQ
Efficiency
How efficient is Moleculin Biotech business performance
The company's return on equity has shrunk by 80% QoQ
Moleculin Biotech's return on assets has shrunk by 55% YoY and by 19% QoQ
Dividends
What is MBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MBRX.
Financial health
How did Moleculin Biotech financials performed over time
The total liabilities has surged by 127% year-on-year and by 92% since the previous quarter
MBRX's quick ratio has dropped by 64% year-on-year but it is up by 40% since the previous quarter
The company's equity has shrunk by 100% YoY and by 99% QoQ
MBRX's debt is down by 28% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.